Revolution Medicines (RVMD) Q3 2026 Earnings Call: Guidance and Outlook
The company reiterated its full year 2026 operating expense guidance and provided commentary on expected expense increases for 2027.
About Revolution Medicines. Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers.
$2.1 billion to $2.2 billion for full year 2026, including $270 million to $290 million of stock-based compensation.
Outlook
Operating expenses
Full year 2027 GAAP operating expenses are expected to increase from the current GAAP operating expense run rate due to expanded investments in the RAS(ON) inhibitor portfolio and global commercial infrastructure.
Gross to net discount
Expected to increase within the anticipated 20% to 30% range as payer mix and discounts mature.
Channel inventory
Expected to be managed at approximately 2 weeks over the long term.
Dombey's summary of the Revolution Medicines Q3 2026 earnings call held Nov 4, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
